Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 53 Next >>

Filter Applied: multiple sclerosis,treatment of (Click to remove)

Multiple Sclerosis
NEJM 378:169-180, Reich, D.S.,et al, 2018

"Undiagnosing" Multiple Sclerosis
Neurol 78:1986-1991,1904, Solomon, A.J.,et al, 2012

Changes in the Ascertainment of Multiple Sclerosis
Neurol 65:1066-1070, Marrie,R.A.,et al, 2005

The Optic Nerve Should Graduate to Be the Fifth Lesion Site for the Diagnosis of Multiple Sclerosis
Neurol 102:e207919, Galetta,S. & Brownlee, W., 2024

Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024

Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020

Progressive multifocal leukoencephalpathy after fingolimod treatment
Neurol 90:1815-e1821, Berger, J.R.,et al, 2018

Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017

Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012

Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients with Multiple Sclerosis
Arch Neurol 69:1259-1269, Radue, E.W.,et al, 2012

Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Arch Neurol 68:186-191, Miravalle,A.,et al, 2011

Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011

Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010

Evidence Report: The Efficacy and Safety of Mitoxantrone (Novantrone) in the Treatment of Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 74:1463-1470, Marriott,J.J., et al, 2010

Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010

Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009

Severe Cardiac Failure in a Patient with Multiple Sclerosis Following Low-Dose Mitoxantrone Treatment
Neurol 73:991-993, D�rr,J.,et al, 2009

Tumefactive Demyelination: An Approach to Diagnosis and Management
JNNP 84:1047-1053, Hardy, T.A. & Chataway, J., 2009

Mlutiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-Up
Arch Neurol 65:727-732, The Optic Neuritis Study Group, 2008

Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008

Efficacy and Safety of Oral Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase LLB Study
Lancet 372:1463-1472, Kappos,L.,et al, 2008

Multiple Sclerosis
Lancet 372:1502-1517, Compston,A. &Coles,A., 2008

Combining Beta Interferon and Atorvastatin May Increase Disease Activity in Multiple Sclerosis
Neurol 71:1390-1395,1386, Birnbaum,G.,et al, 2008

Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007

Mangnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results
Arch Neurol 64:1292-1298, Barkhof,F.,et al, 2007

Diagnosis and Treatment of Multiple Sclerosis
BMJ 332:525-527, Murray,T.J., 2006

Magnetic Resonance Imaging as a Surrogate Outcome Measure of Disability in Multiple Sclerosis: Have We Been Overly Harsh in Our Assessment?
Ann Neurol 59:597-605, Goodin,D.S., 2006

Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006

Oral Simvastin Treatment in Relapsing-Remitting Multiple Sclerosis
Lancet 363:1607-1608,1570, Vollmer,T.,et al, 2004

Interferon Beta-1a for Brain Tissue Loss in Patients at Presentation with Syndromes Suggestive of Multiple Sclerosis: A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 364:1489-1496,1463, Filippi,M.,et al, 2004

Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004

Evidence for Widespread Axonal Damage at the Earliest Clinical Stage of Multiple Sclerosis
Brain 126:433-437, Filippi,M.,et al, 2003

High- and Low-Risk Profiles for the Development of Multiple Sclerosis Within 10 Years After Optic Neuritis
Arch Ophthalmol 121:944-949, Optic Neuritis Study Group, 2003

Application of the New McDonald Criteria to Patients with Clinically Isolated Syndromes Suggestive of Mulitple Sclerosis
Ann Neurol 52:47-53, Dalton,C.M.,et al, 2002

Cardiac Adverse Effects Associated with Mitoxantrone (Novantrone) Therapy in Patients with MS
Neurol 59:909-913, Ghalie,R.G.,et al, 2002

Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1505-1513, Li,D.K.B.,et al, 2001

PRISMS-4: Long-Term Efficacy of Interferon-B-1a in Relapsing MS
Neurol 56:1628-1636,1620, The PRISMS Study Group, 2001

Glatiramer Acetate (Copaxone) Treatment in Relapsing-Remitting MS
Neurol 54:813-817, Ge,Y.,et al, 2000

Clinicopath Conf,Wegener's Granulomatosis with Pachymeningeal Granulomatous Inflammation, Case 9-1999
NEJM 340:945-953, , 1999

Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020

Misdiagnosis of Multiple Sclerosis
Neurol 92:15-16, Brownlee, W.J., 2018

Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011

Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008

Guidelines For Using Proton MR Spectroscopy in Multicenter Clinical MS Studies
Neurol 69:1942-1952, De Stefano,N.,et al, 2007

Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004

Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001

Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol 56:1079-1084, Rudick,R.A., 1999



Showing articles 0 to 50 of 53 Next >>